Project Grant R01AI181270
Award Date
6/5/24
Completion Date
4/30/29
Dollars Obligated
$1.5M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
This Project Grant award of $755,225.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports the development of a COVID-19 vaccine candidate targeting conserved antigens from both Sarbecovirus and Merbecovirus lineages. The goal is to create a vaccine that can provide broad protection against emerging pandemic coronaviruses. The project aims to 1) develop a T cell-inducing, mucosal vaccine using...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $502,075 to investigate the impact of mucosal adjuvanted vaccines on virus transmission in preclinical animal models for SARS-CoV-2 and influenza. The research aims to compare the protective effects of intranasal mucosal adjuvanted vaccines versus intramuscular parenteral vaccines, and analyze their impact on host...
This Cooperative Agreement award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will test a novel vaccine approach designed to generate broad and durable antibody responses against SARS-CoV-2. The $2,870,428 award, with a performance period from May 2024 to April 2029, will evaluate the safety and immunogenicity of a T follicular helper (Tfh)-targeting vaccine adjuvant, "S3",...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop next-generation pertussis vaccines that can elicit mucosal immunity and prevent nasal colonization by the Bordetella pertussis bacteria. The $657,506 award will fund research at The Ohio State University to test a subunit vaccine containing novel T cell antigens and adjuvants that can stimulate...
The University of Maryland, Baltimore has been awarded a $247,750 Project Grant under the National Institute of Allergy and Infectious Diseases' (NIAID) Allergy and Infectious Diseases Research program (CFDA 93.855). The grant, titled "Structural Investigations of Coronavirus Spike Protein," aims to characterize the structural impacts of N-glycan maturation on the SARS-CoV-2 spike protein, which is a critical component in COVID-19 vaccines. The research will utilize innovative...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $705,557 to Emory University to conduct research on the coordination of innate and cellular mucosal immunity in SARS-CoV-2 clearance. The key objectives are to determine the contribution of monocytes in promoting T cell responses and viral control within the respiratory tract, and to define the effector mechanisms of...
This $15,981,588 project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases aims to develop pan-coronavirus vaccines. Led by Washington University, the collaborative program includes eleven laboratories seeking to design optimized B and T cell antigens conferring broad immunity against sarbecoviruses and merbecoviruses. The three-year award beginning September 2022 supports three integrated research projects and two centralized cores. Project 1...
This Project Grant award of $582,618 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the role of RNA epigenetic modifications, specifically N6-methyladenosine (m6A) and pseudouridine (Ψ), in regulating SARS-CoV-2 replication and pathogenesis. The goal is to determine how these modifications modulate viral RNA metabolism, gene expression, innate and adaptive immunity,...
The Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $125,160.00 to The Ohio State University to characterize a novel bacterial immune system with unknown mechanisms. The project aims to use cryogenic electron microscopy and biochemical/cellular assays to define the structure, assembly, and functions of a two-component system (Component A and Component B) involved in...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,380,350 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University for the project "Mechanisms of Immune Protection Against Respiratory Viruses". The funding supports a comprehensive research plan with two main goals: (A) defining the mechanisms of germinal center persistence and generation of long-lived memory B cells and plasma cells after...